Tekla Life Sciences Investors
HQLNYSEFinancial Services● Active
$16.71
$-0.21(-1.24%)
Market Cap$508120721
P/E Ratio—
52W High$18.46
52W Low$12.34
Tekla Life Sciences Investors (HQL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HQL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-09 | 2024-09 | 2023-09 | 2022-09 | 2021-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $86.39M | $86.69M | $39.39M | $31.86M | $45.02M |
| Cost of Revenue | $0.00M | $0.00M | $5.24M | $5.55M | $6.08M |
| Gross Profit | $86.39M | $86.69M | $18.28M | $26.31M | $38.95M |
| Gross Margin %(computed) | 100.00% | 100.00% | 46.41% | 82.58% | 86.50% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | ($0.00M) | $0.00M |
| G&A Expenses | $0.74M | $1.33M | $0.90M | $1.08M | $0.84M |
| Total Operating Expenses | $0.79M | $1.39M | $1.17M | $1.35M | $1.16M |
| Operating Income | $85.59M | $85.30M | ($5.24M) | ($104.60M) | $64.53M |
| Operating Margin %(computed) | 99.08% | 98.40% | -13.31% | -328.30% | 143.32% |
| Interest Income | $0.35M | $1.04M | $0.20M | $0.05M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | $85.59M | $85.30M | $22.35M | ($104.60M) | $64.53M |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | $85.59M | $85.30M | $22.35M | ($104.60M) | $64.53M |
| Net Margin %(computed) | 99.08% | 98.40% | 56.75% | -328.30% | 143.32% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.96 | $3.04 | $0.79 | $-4.07 | $2.66 |
| Wtd Avg Shares | 28.87M | 28.06M | 28.29M | 25.68M | 24.26M |
| EBITDA | $85.59M | $87.22M | $49.95M | ($101.62M) | $68.68M |
| EBITDA Margin %(computed) | 99.08% | 100.61% | 126.83% | -318.92% | 152.54% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Tekla Life Sciences Investors data
About Tekla Life Sciences Investors (HQL) Income Statement
Tekla Life Sciences Investors (HQL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HQL reported revenue of $0.09B, gross profit of $0.09B (gross margin 100.00%), and net income of $0.09B — a net profit margin of 99.08%.
Frequently asked questions
HQL · 4 questionsTekla Life Sciences Investors (HQL) reported revenue of $0.09B for 2025, down 0.3% year-over-year.
HQL revenueHQL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08